The Supreme Court appeared skeptical of a challenge brought by a doctors’ group against the Food and Drug Administration’s (FDA) loosening of regulations of the abortion pill mifepristone.
In oral arguments on March 26, several justices seemed to question whether the doctors’ group had a right to bring the challenge, known in legal parlance as standing—a key argument in the government’s case.